Hainan Shuangcheng Pharmaceuticals Co., Ltd.

Symbol: 002693.SZ

SHZ

5.69

CNY

Market price today

  • -39.5632

    P/E Ratio

  • 2.2749

    PEG Ratio

  • 2.36B

    MRK Cap

  • 0.00%

    DIV Yield

Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693-SZ) Stock Price & Analysis

Shares Outstanding

414.63M

Gross Profit Margin

0.65%

Operating Profit Margin

-0.44%

Net Profit Margin

-0.32%

Return on Assets

-0.08%

Return on Equity

-0.13%

Return on Capital Employed

-0.13%

Company general description and statistics

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
CEO:Mr. Jianming Li
Full-time employees:414
City:Haikou
Address:No. 16 Xingguo Road
IPO:2012-08-08
CIK:

Hainan Shuangcheng Pharmaceuticals Co., Ltd. researches, develops, manufactures, and markets synthesized peptide drugs and active pharmaceutical ingredients worldwide. It offers somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate for injections, as well as vitamin B6. The company was founded in 2000 and is based in Haikou, the People's Republic of China.

General Outlook

In simple terms, Hainan Shuangcheng Pharmaceuticals Co., Ltd. has 414.629 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.654% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.443%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.324%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.080% return, is a testament to Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s adeptness in optimizing resource deployment. Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.128%. Furthermore, the proficiency of Hainan Shuangcheng Pharmaceuticals Co., Ltd. in capital utilization is underscored by a remarkable -0.131% return on capital employed.

Stock Prices

Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $6.28, while its low point bottomed out at $6.18. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Hainan Shuangcheng Pharmaceuticals Co., Ltd.'s stock market.

Liquidity Ratios

Analyzing 002693.SZ liquidity ratios reveals its financial health of the firm. The current ratio of 101.44% gauges short-term asset coverage for liabilities. The quick ratio (31.33%) assesses immediate liquidity, while the cash ratio (13.68%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio101.44%
Quick Ratio31.33%
Cash Ratio13.68%

Profitability Ratios

002693.SZ profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -44.25% underscores its earnings before tax deductions. The effective tax rate stands at 14.47%, revealing its tax efficiency. The net income per EBT, 73.33%, and the EBT per EBIT, 99.78%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -44.35%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-44.25%
Effective Tax Rate14.47%
Net Income per EBT73.33%
EBT per EBIT99.78%
EBIT per Revenue-44.35%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.01, it details the span from stock purchase to revenue.

cards.indicatorcards.value
Days of Sales Outstanding31
Days of Inventory Outstanding411
Operating Cycle438.21
Days of Payables Outstanding85
Cash Conversion Cycle353
Receivables Turnover13.43
Payables Turnover4.30
Inventory Turnover0.89
Fixed Asset Turnover0.44
Asset Turnover0.25

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, 0.02, and free cash flow per share, -0.10, depict cash generation on a per-share basis. The cash per share value, 0.06, showcases liquidity position. A payout ratio of -0.12 highlights the portion of earnings distributed as dividends. Lastly, the operating cash flow sales ratio, 0.04, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share0.02
Free Cash Flow per Share-0.10
Cash per Share0.06
Payout Ratio-0.12
Operating Cash Flow Sales Ratio0.04
Free Cash Flow to Operating Cash Flow Ratio-5.42
Cash Flow Coverage Ratio0.05
Short Term Coverage Ratio0.75
Capital Expenditure Coverage Ratio0.16
Dividend Paid and Capex Coverage Ratio0.14

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 20.74%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.36, we discern the balance between debt and equity financing. The long-term debt to capitalization, 25.08%, and total debt to capitalization, 26.34%, ratios shed light on its capital structure. An interest coverage of -9.68 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio20.74%
Debt Equity Ratio0.36
Long Term Debt to Capitalization25.08%
Total Debt to Capitalization26.34%
Interest Coverage-9.68
Cash Flow to Debt Ratio0.05
Company Equity Multiplier1.72

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 0.56, provides a glimpse into top-line earnings distributed across each share. Net income per share, -0.12, reflects the portion of profit attributed to each share. The book value per share, 1.12, represents the net asset value distributed per share, while the tangible book value per share, 0.82, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share0.56
Net Income Per Share-0.12
Book Value Per Share1.12
Tangible Book Value Per Share0.82
Shareholders Equity Per Share1.12
Interest Debt Per Share0.37
Capex Per Share-0.12

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, -14.13%, indicates top-line expansion, while the gross profit growth, -13.62%, reveals profitability trends. EBIT growth, -198.81%, and operating income growth, -198.81%, offer insights into operational profitability progression. The net income growth, -497.24%, showcases bottom-line expansion, and the EPS growth, -479.71%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth-14.13%
Gross Profit Growth-13.62%
EBIT Growth-198.81%
Operating Income Growth-198.81%
Net Income Growth-497.24%
EPS Growth-479.71%
EPS Diluted Growth-479.71%
Weighted Average Shares Growth3.00%
Weighted Average Shares Diluted Growth3.00%
Dividends per Share Growth-24.25%
Operating Cash Flow Growth-53.84%
Free Cash Flow Growth-383.65%
10-Year Revenue Growth per Share49.39%
5-Year Revenue Growth per Share-32.99%
3-Year Revenue Growth per Share-16.13%
10-Year Operating CF Growth per Share-80.46%
5-Year Operating CF Growth per Share-76.20%
3-Year Operating CF Growth per Share206.15%
10-Year Net Income Growth per Share-171.99%
5-Year Net Income Growth per Share30.03%
3-Year Net Income Growth per Share39.21%
10-Year Shareholders Equity Growth per Share-48.70%
5-Year Shareholders Equity Growth per Share-13.50%
3-Year Shareholders Equity Growth per Share-8.39%
10-Year Dividend per Share Growth per Share-81.30%
5-Year Dividend per Share Growth per Share-50.18%
3-Year Dividend per Share Growth per Share-14.72%
Receivables Growth-60.07%
Inventory Growth13.60%
Asset Growth-11.83%
Book Value per Share Growth-10.86%
Debt Growth-29.35%
R&D Expense Growth-45.49%
SGA Expenses Growth-12.02%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 3,334,154,564.3, captures the company's total value, considering both debt and equity. Income quality, -0.16, assesses the reliability of reported earnings. The sales, general, and administrative to revenue ratio, 0.08, gauges operational efficiency, while the research and development to revenue, 3.37%, highlights investment in innovation. The ratio of intangibles to total assets, 21.39%, indicates the value of non-physical assets, and capex to operating cash flow, -422.67%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value3,334,154,564.3
Income Quality-0.16
Sales General and Administrative to Revenue0.08
Research and Development to Revenue3.37%
Intangibles to Total Assets21.39%
Capex to Operating Cash Flow-422.67%
Capex to Revenue-20.85%
Capex to Depreciation-93.40%
Graham Number1.74
Return on Tangible Assets-8.04%
Graham Net Net-0.48
Working Capital-4,706,205
Tangible Asset Value345,864,059
Net Current Asset Value-150,366,651
Average Receivables28,662,930
Average Payables16,317,120
Average Inventory69,859,833.5
Days Sales Outstanding25
Days Payables Outstanding84
Days of Inventory On Hand362
ROIC-11.70%
ROE-0.11%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 5.47, and the price to book ratio, 5.47, reflect the market's valuation relative to the company's book value. The price to sales ratio, 12.85, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -59.35, and price to operating cash flows, 321.26, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio5.47
Price to Book Ratio5.47
Price to Sales Ratio12.85
Price Cash Flow Ratio321.26
Price Earnings to Growth Ratio2.27
Enterprise Value Multiple-74.89
Price Fair Value5.47
Price to Operating Cash Flow Ratio321.26
Price to Free Cash Flows Ratio-59.35
Price to Tangible Book Ratio6.77
Enterprise Value to Sales14.13
Enterprise Value Over EBITDA99.92
EV to Operating Cash Flow286.45
Earnings Yield-1.59%
Free Cash Flow Yield-1.18%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Hainan Shuangcheng Pharmaceuticals Co., Ltd. (002693.SZ) on the SHZ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -39.563 in 2024.

What is the ticker symbol of Hainan Shuangcheng Pharmaceuticals Co., Ltd. stock?

The ticker symbol of Hainan Shuangcheng Pharmaceuticals Co., Ltd. stock is 002693.SZ.

What is company IPO date?

IPO date of Hainan Shuangcheng Pharmaceuticals Co., Ltd. is 2012-08-08.

What is company current share price?

Current share price is 5.690 CNY.

What is stock market cap today?

The market cap of stock today is 2359239010.000.

What is PEG ratio in 2024?

The current 2.275 is 2.275 in 2024.

What is the number of employees in 2024?

In 2024 the company has 414.